Healthcare

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transp...

This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market. The study highlights some of the emerging business models supporting the development and adoption of innovative diagnostic tests. The Asia-Pacif...

China is one of the fastest growing healthcare markets in the world. Traditionally, healthcare services have been dominated by the public sector; however, 2014 onward, the trend reversed with greater private sector participation. China still faces a number of challenges: unequal distribution of healthcare resources across the country; lack of an ef...

Clinical laboratories are an essential part of the health industry. Approximately 80% of physicians' diagnoses is estimated to be the result of laboratory tests. The constant pressure to reduce healthcare spending is shifting healthcare application in favor of the laboratory, making it a more valuable part of the treatment plan. Vietnam CLT marke...

The market for healthcare services in Malaysia is less developed, with many clinical testing services being unavailable outside of cities. Unsubstantiated disease and unconfirmed mortality diagnoses are common in the country despite universal care, significant mixed investment in the local healthcare system, and health expenditure favourable to oth...

This study focuses on clinical lab services in Thailand. A detailed analysis is provided on clinical testing services at public hospital labs and private hospital labs. Specialised labs are integrated into the independent reference labs segment. Certain trends with regard to physician office labs (POLs) in retail clinics have been mentioned in the ...

Healthcare expenditure in Singapore is expected to grow, fueled by factors such as rising incomes and a progressively aging population. Diagnostics has emerged as a way for earlier and better identification of diseases to control rising healthcare costs in Singapore. Hence, the country has become a natural choice for many global diagnostic companie...

10 Jan 2018  |  Asia Pacific

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Ko...